Abstract

Purpose: To evaluate the effect of hyperin in cisplatin-induced liver injury in mice.
Methods: Mice were pretreated with hyperin at doses of 25 mg/kg and 50 mg/kg, respectively, for six days, and intraperitoneal injection of cisplatin (40 mg/kg) was administrated one hour after the final intragastric administration of hyperin. Twenty-four hours later, blood and liver were collected for further research.
Results: A single injection of cisplatin (40 mg/kg) for 24 h significantly increased serum alanine and aspartate aminotransferases (ALT/AST) and gamma glutamyl transferase (GGT) activities, whereas hyperin reversed cisplatin-induced such increases. Liver histopathological examination further demonstrated the protection of hyperin against cisplatin-induced liver injury. Further results showed hyperin reversed cisplatin-induced the increase in content of malondialdehyde (MDA) and the decrease in level of total antioxidant capacity (T-AOC) in liver. Moreover, hyperin increased the levels of superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPx), glutathione-s transferase (GST) in cisplatin-induced liver.
Conclusion: Hyperin inhibits cisplatin-induced hepatic oxidative stress, which contributes greatly to the amelioration of cisplatin-induced liver injury in mice.
Key words: Cisplatin. Chemical and Drug Induced Liver Injury. Oxidative Stress. Mice.
Introduction

Chemotherapy plays an important role in the treatment of cancer nowadays. In spite of the benefits available, it is also accompanied with potent side effects. The severe reactions of chemotherapeutic agents are a major limitation to the use of drug in the clinic.

Cisplatin is a potent chemotherapeutic agent used for the treatment of a wide range of cancer such as ovarian, cervical, and head and neck cancers. Cisplatin is becoming increasingly a favor to clinical doctors attributed to its unique clinical benefit. Unfortunately, cisplatin therapy brings about undesirable side effects, including renal dysfunction, ototoxicity, nausea and vomiting, and hepatotoxicity. Hepatotoxicity is not considered to be a dose limiting toxicity for cisplatin, but liver toxicity can occur when it is administered at high doses, which has been an obstacle for the further usage of cisplatin.

Flavonoids are plant polyphenols found in vegetables, fruit and beverages of plant origin, and are well known for owning to their considerable health benefits. Hyperin, a flavonoid compound occurring in natural plants, has been demonstrated to exert a variety of biological activities, including antioxidant, anti-inflammatory, anticancer, and cardiovascular protective effects. Besides, hyperin is reported to have hepato-protective activity. Furthermore, hyperin induces apoptosis in cancer cell and sensitizes it to cisplatin treatment. It has also been demonstrated that hyperin protects against cisplatin-induced acute kidney injury in mice. However, the effect of hyperin in hepatoprotection during cisplatin administration has not been reported so far. In the present study, the effect of hyperin on cisplatin-induced liver injury was investigated.

Methods

Male ICR mice (body weight 18-22 g) were obtained from Yangzhou University (Yangzhou, China). The mice had access to standard diet and water was given ad libitum. Experiments were conducted in accordance with the institutional animal care guidelines approved by Huai’an Institute for Food and Drug Control. The animals were randomly separated into 4 groups. The mice in group 1 were served as vehicle group, which were given orally 0.9% normal saline throughout the experiment. The mice in group 2 were served as cisplatin group, which were injected intraperitoneally (i.p.) cisplatin (40 mg/kg, dissolved in 0.9% normal saline) only once on the sixth day. The mice in groups 3, 4 were served as hyperin (25, 50 mg/kg) + cisplatin groups, which were administrated intragastrically (i.g.) hyperin (25, 50 mg/kg per day) for six consecutive days, and one hour after the final administration of hyperin, cisplatin was injected intraperitoneally. The dose selection was based on the literatures and our preliminary experiment. 24 hours later, blood samples were collected by extirpating the eyeball, approximately 0.8 ml per mice, and then mice were sacrificed, finally their livers were removed for further research.

Drugs and reagents

Hyperin (HPLC purity > 98%) was purchased from Nanjing Goren Biotech Co., Ltd. (Nanjing, China). Cisplatin was purchased from Sigma Chemical Co. (St. Louis, MO). The kits of AST, ALT, GGT, MDA, T-AOC, SOD, CAT, GSH, GST and GPx were all purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

Serum biochemistry

The blood samples obtained were allowed to keep for 2 h at room temperature, and then centrifugated at 3.500 rpm for 10 min. The supernatant serum was transferred to new tubes for further analysis. Serum alanine/
aspartate aminotransferase (ALT/AST), gamma glutamyl transferase (GGT) activities were determined with commercial kits according to the instructions of manufacturer.

**Histopathological examination**

The formalin-fixed liver samples were embedded in paraffin, and then sectioned 5 μm. The sections were stained with haematoxylin and eosin. The slides obtained were mounted and visualized under a light microscope for histological evaluation.

**Measurement of lipid peroxidation (LPO) in liver**

Liver tissue was homogenized in ice-cold 0.9% normal saline. Malondialdehyde (MDA) was assayed by the manufacturer’s instruction. MDA reacts with TBA to form the product with the wavelength of maximum absorption at 532 nm. The corresponding protein concentrations were measured according to the Bradford assay. The MDA level in liver was calculated based on protein concentrations of samples and expressed as nmols of MDA/mg protein.

**Determination of total antioxidant capacity (T-AOC)**

In the presence of antioxidants in the liver, Fe^{3+} was reduced to Fe^{2+}. The latter can form a stable complex, which was measured with colorimetric assay. The specific process was carried out according to the instruction of manufacture. The results were assessed based on protein concentration of the corresponding sample.

**Measurement of GSH content**

The reduced GSH in liver was detected following the instructions on the commercial kits. The final absorbance was measured at 420 nm and results were normalized by the protein concentration of corresponding sample as measured by Bradford assay.

**Enzymatic assays**

Hepatic tissue was homogenized in precooled normal saline and centrifuged at 3500 r/min for 15 min. The supernatant obtained was used for the measurement of SOD, CAT, GPx and GST, which were determined according to the manufacturer’s instructions respectively. The results were assessed based on protein concentration of the corresponding sample.

**Statistical analysis**

All of the values were presented as mean ± standard error (SE). Statistical analysis was performed using one-way analysis of variance (ANOVA) test with LSD and homogeneity of variance test. P<0.05 was considered as statistically significant difference.

■ **Results**

**Hyperin prevented cisplatin-induced the increase of serum ALT, AST and GGT activities**

ALT, AST and GGT activities in serum are the biomarkers for liver function, and their significant elevation generally reflects acute liver injury. As shown in Figure 1, the serum activities of ALT, AST and GGT obviously increased in cisplatin-treated mice as compared to control (P<0.001). Meanwhile, oral administration of hyperin (50 mg/kg) for 6 days could obviously prevent cisplatin-induced such increase (P<0.01). Hyperin (25 mg/kg) had no effect on the elevated serum ALT and GGT activities induced by cisplatin, while the increased AST activity obviously decreased with the administration of hyperin (25 mg/kg) (P<0.05) (Figure 1).
Hyperin protects against cisplatin-induced liver injury in mice

Niu C et al.

Acta Cir Bras. 2017;32(8):633-640

Figure 1 - Hyperin prevented cisplatin-induced the increase of serum ALT, AST and GGT activities. (A) The serum ALT and AST activities. (B) The serum GGT activity. Data were shown as means ± SE, (n=9-10). *** p<0.001 vs. control group, # p<0.05, ## p<0.01, vs. cisplatin-treated group.

Histopathological analysis

As compared to control liver (Figure 2a), the liver treated with cisplatin exhibited serious liver damage, indicated by obvious hepatocyte steatosis with vacuoles in the cytoplasm (Figure 2b). Interestingly, hyperin (50 mg/kg) strongly prevented cisplatin-induced hepatic lesions (Figure 2c).

Figure 2 - Hyperin reversed cisplatin-induced liver histopathological changes. Liver sections were stained with hematoxylin–eosin. (a) Control group, (b) Cisplatin only group, (c) Cisplatin+ Hyperin (50 mg/kg) group, (x100).

Hyperin reversed cisplatin-induced the changes of MDA and T-AOC levels in liver.

As shown in Figure 3, a single administration of cisplatin significantly increased MDA content and decrease T-AOC level in liver (P<0.001, P<0.01), while hyperin (50 mg/kg) pretreatment reversed such changes (P<0.05). However, pretreatment with hyperin (25 mg/kg) had no effect on liver MDA and T-AOC levels.

Figure 3 - Hyperin reversed cisplatin-induced the changes of MDA and T-AOC levels in liver. (A) Liver MDA content, (B) Liver T-AOC level. Data were shown as means ± SE, (n=9-10). **p<0.01, ***p<0.001 vs. control, #p<0.05 vs cisplatin-treated group.

Hyperin increased cisplatin-induced the decreased activities of SOD and CAT in liver

The results in Figure 4 showed that there was a significant decrease in hepatic SOD and CAT activities in cisplatin-induced mice (P<0.05, P<0.01), the hepatic activities of SOD and CAT obviously increased with the administration of hyperin (50 mg/kg) (P<0.05).
However, there were no obvious improvements in hepatic activities of SOD and CAT in hyperin (25 mg/kg)-treated mice.

Figure 4 - Hyperin increased cisplatin-induced the decreased activities of SOD and CAT in liver. (A) Liver SOD activity, (B) Liver CAT activity. Data were shown as means ± SE, (n=9-10). *p<0.05, **p<0.01 vs. control, #p<0.05 vs. cisplatin-treated group.

Hyperin increased the levels of GSH, GPx and GST in cisplatin-induced liver

There is a significant increase of GSH level in hyperin (50 mg/kg)-treated mice compared with cisplatin (40 mg/kg) group (P<0.05). Cisplatin decreased hepatic activities of GPx and GST (P<0.001, P<0.01), while hyperin (50 mg/kg) could increase the decreased hepatic activities of GPx and GST induced by cisplatin (P<0.05). However, hyperin (25 mg/kg) had no effect on cisplatin-induced decreased levels of GPx and GST in liver (Figure 5).

Figure 5 - Hyperin increased the levels of GSH, GPx and GST in cisplatin-induced liver. (A) Liver GSH level, (B) Liver GPx activity, (C) liver GST activity. Data were shown as means ± SE, (n=9-10). **p<0.01, ***p<0.001 vs. control, #p<0.05 vs. cisplatin-treated group.

Discussion

The significant increase of ALT, AST and GGT activities in serum is commonly used as a marker for liver injury. As shown in Figure 1, hyperin can prevent cisplatin-induced liver injury, as indicated by the decreased ALT, AST, and GGT activities in serum which are elevated after cisplatin treatment. Histological analysis further confirmed the protection of hyperin against cisplatin-induced liver injury (Figure 2). It is reported that hyperin could protect against hepatotoxin-induced liver diseases. In addition, hyperin has been demonstrated
to prevent cisplatin-induced renal damage in mice\textsuperscript{19}. The present results demonstrated the protection of hyperin against cisplatin-induced liver injury.

There are increasing evidences that oxidative stress plays a critical role in liver diseases\textsuperscript{23-25}. Harmful stimulation induces the excessive generation of reactive oxygen species (ROS) in liver. Level of cellular antioxidant depletion exceeds the level of ROS production and ultimately leads to the development of liver injury. The changes of oxidant and antioxidant system in liver of mice exposure to cisplatin with or without preadministration of hyperin were investigated. As shown in Figure 3, there was a significant decrease in T-AOC level and increase in MDA content in cisplatin-treated liver, indicating that cisplatin could decrease the defense of anti-oxidative system and induce liver oxidative stress injury. While hyperin pretreatment reversed such changes, suggesting that hyperin could improve the defensive ability of anti-oxidant system against hepatic oxidative stress injury.

Cellular antioxidant enzymes play an important role in defense against oxidative stress. SOD and CAT, the main cellular antioxidant enzymes, function mutually to scavenge ROS produced during the oxidative stress\textsuperscript{26}. SOD converts the superoxide into hydrogen peroxide\textsuperscript{27}, while CAT can then catalyze it into toxic free substances\textsuperscript{28}. As shown in Figure 4, hyperin prevented the decrease in liver activities of SOD and CAT induced by cisplatin, suggesting that SOD and CAT may participate in the protection of hyperin against cisplatin-induced liver oxidative stress injury. GSH, an important part of the anti-oxidative defense system, is a non-enzymatic antioxidant plays a vital role in protection of cells against exogenous toxic substances\textsuperscript{29}. In the research, we detected the GSH content to evaluate the protective effect of hyperin against cisplatin-induced oxidative stress injury. Our results in Figure 5A showed that GSH content in liver of mice exposure to cisplatin significantly increased, suggesting cisplatin may cause oxidative stress injury and body induces the excess increase of GSH to resist thus injury. While hyperin could further enhance the GSH content, suggesting hyperin protects hepatocytes against the damage of cisplatin via increasing the GSH content.

GPx and GST are glutathione-related enzymes and they participate in the oxidative stress process with GSH. GPx converts H\textsubscript{2}O\textsubscript{2} and hydroperoxides to non-toxic products in the presence of GSH and GST catalyzes the conjugation of reactive metabolites with GSH\textsuperscript{30,31}. In the present study, the decreased liver activities of GPx and GST in cisplatin-induced mice significantly increased with the pretreatment of hyperin (Figure 5B,C), indicating that hyperin protects against cisplatin-induced liver oxidative stress injury via enhancing the activities of glutathione-related enzymes.

\section*{Conclusion}

Hyperin protects against the liver injury induced by cisplatin via inhibiting liver oxidative stress injury in mice. Further research is in progress in our laboratory to explore the effect of hyperin on antitumor activity of cisplatin.

\section*{References}


Correspondence:
Dr. Chengwei Niu
College of Pharmacy, Jiangsu Food and Pharmaceutical Science College
4 Meicheng Road, Huai’an 223001 China
niuchengwei10@126.com

Received: Apr 12, 2017
Review: June 13, 2017
Accepted: July 18, 2017

Conflict of interest: none
Financial sources: Science and Technology Plan Project of Huai’an (HAG2015019), and Practice Innovation Training Projects of Jiangsu College students (201513104006Y).

1Research performed at College of Pharmacy, Jiangsu Food and Pharmaceutical Science College, and Pathology Department, Huai an Hospital of Huai’an, China.